Following righteous laboratory pra...

Following righteous laboratory practice (GLP) for nonclinical laboratory studies has been required since 21 CFR 58 went into weight in 1979 for all studies that support FDA research and marketing permits, in the same state [i]or[/i] condition as investigational new medicine applications (INDs), new drug applications (NDAs), and biologics licensing applications (BLAs). (1) GLP apply to nonclinical (or preclinical) laboratory studies for regimen and color additives, animal commons additives, human and animal put drugs intos medical devices for human use, biological returnss and electronic products. The intent of the regulation is to